New, even more effective HPV vaccine in sight

September 11, 2013, Medical University of Vienna
New, even more effective HPV vaccine in sight

A recently published paper by the Department of Immunodermatology at the Medical University of Vienna has unveiled a second-generation prophylactic HPV vaccine. In future, this will not only protect against the majority of genital high and low-risk types, but also the types that are responsible for the development of skin warts.

The results of the pre-clinical study, which raises hopes for the future development of a broadly effective vaccine against the Human Papillomavirus (HPV), have recently been published in the highly respected magazine Journal of Investigative Dermatology. The study was carried out by Christina Schellenbacher and a team led by Reinhard Kirnbauer from the Department of Immunodermatology at the MedUni Vienna (headed by Georg Stingl), with the collaboration of working groups from the Vienna University of Veterinary Medicine, the University of Malmö and the Johns Hopkins University (in Baltimore, USA). The next stage involves the vaccine's evaluation in clinical trials.

Unlike with the vaccines that have been available previously, which contain two to four antigens, the researchers adopted a different approach: they put together an individual, new antigen (RG1-VLP) from the 's main capsid protein L1 and auxiliary L2. In laboratory studies, this vaccine demonstrated significantly broader effectiveness against high and low-risk types of HPV compared to the vaccines that are available currently.

New vaccine also effective against hand and foot warts

Unless previous vaccines, the new also protects for the first time against cutaneous, or skin-based, types of HPV. These types of HPV cause hand and foot warts as well as flat warts, primarily among children, but also in adults. These skin changes can cause significant problems, especially for immunosuppressed patients.

Vaccination makes sense for children

The results of the study also raise the prospect of administering the vaccine to children. According to the researchers, this would help effectively prevent the development of during childhood and later infections with genital viruses.

Reinhard Kirnbauer, who is also already the inventor of the existing HPV16 vaccine and therefore the key element of the new vaccine, also highlights two further advantages: "The vaccine has been formulated as a singular antigen (RG1-VLP), offering a prospective economic advantage compared to the existing licensed vaccines and a nine-in-one vaccine that is currently undergoing clinical trials. HPV-VLP vaccines also have an excellent safety profile, which means we are now keen to push ahead with the evaluation of the in clinical studies."

Explore further: 1 in 5 boys got HPV shot in first year recommended

More information: Schellenbacher, C. et al. Efficacy of RG1-VLP Vaccination against Infections with Genital and Cutaneous Human Papillomaviruses, Journal of Investigative Dermatology. DOI: 10.1038/jid.2013.253

Related Stories

1 in 5 boys got HPV shot in first year recommended

August 29, 2013
A new report offers a first look at how many boys are getting shots designed to protect girls from cervical cancer. Health officials say the number getting vaccinated so far is a good start.

HPV vaccination to provide even more protection in future against infections

April 17, 2013
At present over one hundred strains of the human papillomavirus (HPV) are known, fourteen of which can trigger cancer. The HPV vaccinations currently in use provide protection from 70 percent of these cancers. "With the next ...

Hidden strains of HPV found in 'virus-negative' genital warts

July 11, 2013
There are 170 established HPV types. Cancerous human papillomavirus (HPV) viruses are the main cause of cervical cancer, and are found in close to 100% of cervical tumors.

Significant decline of genital warts in young women

July 20, 2012
(Medical Xpress) -- The incidence of condyloma or genital warts (GW) is significantly declining in young women, according to a novel register study from Karolinska Institutet. The researchers suggest that this recent development ...

How cervical cancer vaccines came to be

January 19, 2013
(HealthDay)—The cervical cancer vaccine has turned into one of the biggest success stories in the field.

Report: Teen HPV vaccination rate still lagging

July 25, 2013
(AP)—Disappointed health officials say only about half of teenage girls have gotten a controversial vaccine against cervical cancer—a rate that's changed little in three years.

Recommended for you

Why some cancers affect only young women

October 19, 2018
Among several forms of pancreatic cancer, one of them specifically affects women, often young. How is this possible, even though the pancreas is an organ with little exposure to sex hormones? This pancreatic cancer, known ...

Scientists to improve cancer treatment effectiveness

October 19, 2018
Together with researchers from the University of Nantes and the University of Reims Champagne-Ardenne in France, experts from the National Research Nuclear University MEPhI have recently developed a quantum dot-based microarray ...

Mutant cells colonize our tissues over our lifetime

October 18, 2018
By the time we reach middle age, more than half of the oesophagus in healthy people has been taken over by cells carrying mutations in cancer genes, scientists have uncovered. By studying normal oesophagus tissue, scientists ...

Study involving hundreds of patient samples may reveal new treatment options of leukemia

October 17, 2018
After more than five years and 672 patient samples, an OHSU research team has published the largest cancer dataset of its kind for a form of leukemia. The study, "Functional Genomic Landscape of Acute Myeloid Leukemia", published ...

A 150-year-old drug might improve radiation therapy for cancer

October 17, 2018
A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more sensitive to radiation therapy, according to a recent study led by researchers at The Ohio State University Comprehensive Cancer ...

Loss of protein p53 helps cancer cells multiply in 'unfavourable' conditions

October 17, 2018
Researchers have discovered a novel consequence of loss of the tumour protein p53 that promotes cancer development, according to new findings in eLife.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.